New appointment at Alder Biopharmaceuticals
This article was originally published in Scrip
Executive Summary
The emerging antibody therapeutics company Alder Biopharmaceuticals (US) has named Dr Mark Young senior vice-president of pharmaceutical operations. He was most recently a bioprocess consultant for several biopharmaceutical clients. Before that, Dr Young served as senior vice-president of technical operations at ZymoGenetics.